Slide Stainer Market by Product (Reagent (Stains, Probes, ABS), Equipment (Automated, Manual)), Technology (H&E, IHC, ISH, Cytology), Application (Disease Diagnosis (Cancer) Research), End User (Hospitals, Diagnostic Labs) - Global Forecast to 2027

Abstract
The global slide stainer market is valued at USD 4.3 billion in 2022 and is projected to reach USD 5.9 billion in 2027 at a CAGR of 6.8% from 2022 to 2027. The major factors driving the growth of this market are the high volume of cancer diagnoses, increasing cancer drug research, advancing healthcare infrastructure and expanding geriatric population. However, the high cost of the slide staining systems and the consolidation in the slide stainer system market are factors expected to restrain the growth of this market in the coming years.

“The reagents & kits segment accounted for the largest share of the slide stainer market in 2021.”

The slide stainer market by product is further segmented into the slide stainer market is segmented into reagents & kits, equipment, and consumables & accessories. The reagents & kits dominated the slide stainer products with the high usage of the reagent & kits in the diagnosis and research of various diseases such as cancer, infections and other chronic conditions. The lung pathology-related diagnosis and research-related studies have increased the volume of slide staining.

“The hematoxyline & eosin segment accounted for the largest share of the slide stainer market in 2021.”

The slide stainer market by technology is further segmented into the slide stainer market is segmented into hematoxylin & eosin, immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special staining. The hematoxylin & eosin dominated the slide stainer products. Hematoxylin & eosin is the most used slide staining technique used for the diagnosis and research of cancer, infectious, and other chronic diseases.

“The disease diagnosis application segment is estimated to grow at a rapid rate during the forecast period.”

Based on application, the slide stainer market is segmented into disease diagnosis and medical research. In 2021, the disease diagnosis application accounted for the largest share of the slide stainer market and is projected to grow at the highest CAGR. The increasing cases of cancer, such as breast cancer, gastric cancer, lymphoma, etc., and infections. The prevalence of cancer and various infections is rising, which has boosted the growth rate of the application segment.

“Hospitals & diagnostics centers segment accounted for the largest share of end users of the slide stainer market in 2021.”

The end user segment of the slide stainer market is further segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end users. The dominant share was accounted for by the hospitals and diagnostics centers segment in 2021, which was driven by the high volume of cancer slide staining due to the cancer biopsies, diagnosis and research. Also, the high burden of infections such as COVID-19 and their diagnosis have promoted the segment of the slide stainer end users.

“Asia Pacific is the fastest-growing regional market for slide stainer.”

In 2021, the slide stainer market was further divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America region ruled the market in 2021, followed by Europe. Although, the Asia Pacific region is expected to grow with the fastest growth rate during the forecast period of 2022 to 2027, with the improving healthcare infrastructure, medical investments, vast patient base of geriatric patients and increasing cases of cancer, infections and other chronic complications.

The breakdown of the primary participants’ profiles has been provided below:
•By Company Type: Tier 1: 31%, Tier 2: 46%, and Tier 3: 23%
•By Designation: C-level: 42%, Director-level: 26%, and Others: 32%
•By Region: North America: 35%, Europe: 30%, Asia Pacific: 21%, and Rest of the World: 14%

The key players operating in the slide stainer market include the following:
•F. Hoffmann-La Roche Ltd. (Switzerland)
•Danaher Corporation (US)
•PHC Holdings Corporation (Japan)
•Thermo Fisher Scientific, Inc. (US)
•Merck KGAA (Germany)
•Agilent Technologies, Inc. (US)
•Abcam Plc. (UK)
•Becton, Dickinson and Company (US)
•Siemens Healthineers AG (Germany)
•Biocare Medical, LLC (US)
•Hardy Diagnostics (US)
•General Data Company (US)
•ELITechGroup (France)
•Biogenex (US)
•Histo-Line Laboratories (Italy)
•SLEE MEDICAL GmbH (Germany)
•Amos scientific Pty Ltd. (Australia)
•MEDITE Medical GMBH (Germany)
•Cellpath Ltd (UK)
•Diapath S.P.A. (Italy)
•Bio SB, Inc. (US)
•Rockland Immunochemicals, Inc. (US)
•Cell Signaling Technology, Inc. (US)
•Diagnostic BioSystems, Inc. (US)
•Dakewe Biotech Co., Ltd. (China)

Research Coverage
This report studies the slide stainer market based on product, application, technology, end user and region. The report also analyzes factors (drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total slide stainer market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
•Market Penetration: Comprehensive information on the slide stainer offered by the top 17 players in the market. The report analyzes the slide stainer market by product and region.
•Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various slide stainers across key geographic regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the slide stainer market.
•Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the slide stainer market.

Content
Table of Contents

1INTRODUCTION29
1.1STUDY OBJECTIVES29
1.2MARKET DEFINITION29
1.2.1INCLUSIONS AND EXCLUSIONS29
1.3MARKET SCOPE30
1.3.1GEOGRAPHIC SCOPE31
1.3.2YEARS CONSIDERED31
1.4CURRENCY CONSIDERED31
1.5LIMITATIONS32
1.6MARKET STAKEHOLDERS32
1.7SUMMARY OF CHANGES32
2RESEARCH METHODOLOGY34
2.1RESEARCH DATA34
FIGURE 1RESEARCH DESIGN34
2.1.1SECONDARY DATA35
2.1.1.1Secondary sources36
2.1.2PRIMARY DATA36
FIGURE 2PRIMARY SOURCES36
2.1.2.1Key data from primary sources37
2.1.2.2Key industry insights38
2.1.2.3Breakdown of primary interviews39
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS39
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS39
2.2MARKET SIZE ESTIMATION40
FIGURE 5REVENUE SHARE ANALYSIS ILLUSTRATION: F. HOFFMANN-LA ROCHE AG40
FIGURE 6MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH41
2.2.1GROWTH FORECAST42
FIGURE 7CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS42
FIGURE 8TOP-DOWN APPROACH43
2.3MARKET BREAKDOWN AND DATA TRIANGULATION44
FIGURE 9DATA TRIANGULATION METHODOLOGY44
2.4MARKET SHARE ANALYSIS45
2.5ASSUMPTIONS FOR THE STUDY45
2.6INDICATORS AND ASSUMPTIONS46
2.7RISK ASSESSMENT46
TABLE 1RISK ASSESSMENT46
3EXECUTIVE SUMMARY47
FIGURE 10SLIDE STAINER MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)47
FIGURE 11SLIDE STAINER MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)48
FIGURE 12SLIDE STAINER MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)48
FIGURE 13SLIDE STAINER MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)49
FIGURE 14GEOGRAPHIC SNAPSHOT: SLIDE STAINER MARKET50
4PREMIUM INSIGHTS51
4.1SLIDE STAINER MARKET OVERVIEW51
FIGURE 15RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH51
4.2ASIA PACIFIC SLIDE STAINER MARKET: BY APPLICATION AND COUNTRY (2021)52
FIGURE 16DISEASE DIAGNOSTICS SEGMENT DOMINATED ASIA PACIFIC SLIDE STAINER MARKET, BY APPLICATION, IN 202152
4.3GEOGRAPHIC MIX: SLIDE STAINER MARKET52
FIGURE 17NORTH AMERICA TO DOMINATE SLIDE STAINER MARKET DURING FORECAST PERIOD52
4.4SLIDE STAINER MARKET: GEOGRAPHIC SNAPSHOT53
FIGURE 18CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD53
5MARKET OVERVIEW54
5.1INTRODUCTION54
5.2MARKET DYNAMICS54
FIGURE 19SLIDE STAINER MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES54
5.2.1DRIVERS55
5.2.1.1Rising prevalence of cancer55
TABLE 2INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)55
TABLE 3PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 203556
5.2.1.2Recommendations for cancer screening56
5.2.1.3Increasing healthcare expenditure56
FIGURE 20HEALTH EXPENDITURE PER CAPITA, 2010–201957
FIGURE 21HEALTH EXPENDITURE (% OF GDP), 2010–201957
5.2.1.4Rising geriatric population and subsequent growth in chronic and infectious disease prevalence58
FIGURE 22ESTIMATED INCREASE IN CANCER INCIDENCE (MILLION), 2020 VS. 203058
FIGURE 23ESTIMATED CANCER DEATHS (MILLION), 2020 VS. 203058
5.2.1.5Growing number of private diagnostic centers globally59
5.2.1.6Increasing automation in laboratories59
5.2.1.7Increasing use of AI in histopathology59
5.2.2RESTRAINTS60
5.2.2.1High equipment cost60
 
5.2.3OPPORTUNITIES60
5.2.3.1High-growth opportunities in emerging markets60
FIGURE 24GROWTH IN HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–201961
5.2.3.2Increasing number of clinical trials pertaining to cancer drugs61
5.2.4CHALLENGES61
5.2.4.1Dearth of knowledgeable and skilled technicians61
TABLE 4NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 201862
5.2.4.2Product recalls62
TABLE 5INDICATIVE LIST OF PRODUCT RECALLS FOR SLIDE STAINING EQUIPMENT (2019–2022)62
5.2.4.3Availability of refurbished equipment63
5.3VALUE CHAIN ANALYSIS63
FIGURE 25VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES63
5.4SUPPLY CHAIN ANALYSIS64
FIGURE 26DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES65
5.5TECHNOLOGY ANALYSIS65
5.6PORTER’S FIVE FORCES ANALYSIS66
5.6.1THREAT OF NEW ENTRANTS66
5.6.2INTENSITY OF COMPETITIVE RIVALRY66
5.6.3BARGAINING POWER OF BUYERS66
5.6.4BARGAINING POWER OF SUPPLIERS66
5.6.5THREAT OF SUBSTITUTES66
5.7KEY STAKEHOLDERS AND BUYING CRITERIA67
5.7.1KEY STAKEHOLDERS IN BUYING PROCESS67
FIGURE 27INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS67
TABLE 6INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%)67
5.7.2BUYING CRITERIA67
FIGURE 28KEY BUYING CRITERIA FOR TOP 3 END USERS67
TABLE 7KEY BUYING CRITERIA FOR TOP 3 END USERS68
5.8REGULATORY LANDSCAPE68
TABLE 8INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING SLIDE STAINING MARKET68
5.9PATENT ANALYSIS70
5.10KEY CONFERENCES AND EVENTS IN 2022–202371
TABLE 9LIST OF CONFERENCES AND EVENTS71
5.11PRICING ANALYSIS71
TABLE 10PRICE RANGE FOR SLIDE STAINERS71
5.12TRADE ANALYSIS72
TABLE 11IMPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017–2021 (USD MILLION)72
TABLE 12EXPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017–2021 (USD MILLION)72
5.13ECOSYSTEM ANALYSIS73
TABLE 13ROLE IN ECOSYSTEM73
FIGURE 29KEY PLAYERS OPERATING IN SLIDE STAINER MARKET74
5.14TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES74
6SLIDE STAINER MARKET, BY PRODUCT75
6.1INTRODUCTION76
TABLE 14SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)76
6.2REAGENTS AND KITS76
TABLE 15SLIDE STAINER MARKET FOR REAGENTS AND KITS, BY TYPE, 2020–2027 (USD MILLION)76
6.2.1STAINS77
6.2.1.1Staining is extensively used in diagnosis and research of carcinoma tissue samples77
TABLE 16SLIDE STAINER MARKET FOR STAINS, BY REGION, 2020–2027 (USD MILLION)77
6.2.2BLOCKING SERA AND REAGENTS77
6.2.2.1Blocking sera and reagents prevent nonspecific binding and reduce background noise77
TABLE 17SLIDE STAINER MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2020–2027 (USD MILLION)78
6.2.3DILUENTS AND BUFFERS78
6.2.3.1Diluents and buffers are used for IHC workflow optimization78
TABLE 18SLIDE STAINER MARKET FOR DILUENTS AND BUFFERS, BY REGION, 2020–2027 (USD MILLION)78
6.2.4MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA79
6.2.4.1Fixative reagents are used to immobilize antigens and retain cellular and subcellular structures79
TABLE 19SLIDE STAINER MARKET FOR MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA, BY REGION, 2020–2027 (USD MILLION)79
6.2.5PROBES79
6.2.5.1Probes are widely used in ISH79
TABLE 20SLIDE STAINER MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION)80
6.2.6ANTIBODIES80
6.2.6.1Increasing prevalence of infectious diseases and cancer to drive segment growth80
TABLE 21SLIDE STAINER MARKET FOR ANTIBODIES, BY REGION, 2020–2027 (USD MILLION)81
6.3EQUIPMENT81
TABLE 22SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)81
6.3.1AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS81
6.3.1.1High-throughput efficacy and accuracy of staining biological samples driving segment growth81
TABLE 23KEY BRANDS OF AUTOMATED SLIDE STAINERS82
TABLE 24AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS MARKET, BY REGION, 2020–2027 (USD MILLION)83
6.3.2MANUAL SLIDE STAINING SETS83
6.3.2.1Low cost of manual staining sets to drive segment growth83
TABLE 25KEY BRANDS OF MANUAL SLIDE STAINING SETS83
TABLE 26MANUAL SLIDE STAINERS MARKET, BY REGION, 2020–2027 (USD MILLION)84
6.4CONSUMABLES AND ACCESSORIES84
TABLE 27SLIDE STAINER MARKET FOR CONSUMABLES AND ACCESSORIES, BY REGION, 2020–2027 (USD MILLION)84
7SLIDE STAINER MARKET, BY APPLICATION85
7.1INTRODUCTION86
TABLE 28SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)86
7.2DISEASE DIAGNOSTICS86
TABLE 29SLIDE STAINER MARKET FOR DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2020–2027 (USD MILLION)86
7.2.1BREAST CANCER87
7.2.1.1High prevalence of breast cancer to drive segment growth87
TABLE 30BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 204087
TABLE 31SLIDE STAINER MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)88
7.2.2GASTRIC CANCER88
7.2.2.1Growing prevalence of and increasing research on gastric cancer to drive segment growth88
TABLE 32COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 204088
TABLE 33SLIDE STRAINER MARKET FOR GASTRIC CANCER, BY REGION, 2020–2027 (USD MILLION)89
7.2.3LYMPHOMA89
7.2.3.1IHC and biopsy are preferable tests to diagnose lymphoma89
TABLE 34HODGKIN’S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 202589
TABLE 35NON-HODGKIN’S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 202590
TABLE 36SLIDE STAINER MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)90
7.2.4PROSTATE CANCER90
7.2.4.1IHC tests are used to identify prostate cancer90
TABLE 37PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 202591
TABLE 38SLIDE STAINER MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)91
7.2.5NON-SMALL CELL LUNG CANCER91
7.2.5.1IHC helps analyze adenocarcinoma and squamous carcinoma of lungs through staining of antibodies91
TABLE 39NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 204092
TABLE 40SLIDE STAINER MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)92
7.2.6OTHER DISEASES93
TABLE 41SLIDE STAINER MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)93
7.3MEDICAL RESEARCH94
7.3.1WIDE USE OF TISSUE BIOPSY AND SLIDE STAINING IN DRUG DEVELOPMENT TO DRIVE SEGMENT GROWTH94
TABLE 42SLIDE STAINER MARKET FOR MEDICAL RESEARCH, BY REGION, 2020–2027 (USD MILLION)94
8SLIDE STAINER MARKET, BY TECHNOLOGY95
8.1INTRODUCTION96
TABLE 43SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)96
8.2HEMATOXYLIN & EOSIN (H&E)96
8.2.1WIDE USE OF H&E FOR STAINING VARIOUS BIOLOGICAL SAMPLES DRIVING SEGMENT GROWTH96
TABLE 44HEMATOXYLIN & EOSIN SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)97
8.3IMMUNOHISTOCHEMISTRY (IHC)97
8.3.1AUTOMATION OF IHC TECHNIQUES DRIVING SEGMENT GROWTH97
TABLE 45IMMUNOHISTOCHEMISTRY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)98
8.4IN SITU HYBRIDIZATION (ISH)98
8.4.1EMERGING ISH STAINING TECHNIQUES SUCH AS FISH AND CISH DRIVING SEGMENT GROWTH98
TABLE 46IN SITU HYBRIDIZATION SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)99
8.5CYTOLOGY99
8.5.1WIDE USE OF CYTOLOGY FOR CANCER STUDIES DRIVING SEGMENT GROWTH99
TABLE 47CYTOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)100
8.6MICROBIOLOGY100
8.6.1INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVING SEGMENT GROWTH100
TABLE 48GLOBALLY REPORTED CASES OF INFECTIOUS DISEASES101
TABLE 49MICROBIOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)101
8.7HEMATOLOGY102
8.7.1INCREASING PREVALENCE OF HEMATOLOGY DISORDERS DRIVING SEGMENT GROWTH102
TABLE 50HEMATOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)102
8.8SPECIAL STAINING103
8.8.1SPECIAL STAINING IS USED WHERE ROUTINE H&E TECHNIQUES CANNOT PROVIDE NEEDED INFORMATION103
TABLE 51SPECIAL SLIDE STAINERS OFFERED BY SOME PLAYERS103
TABLE 52SPECIAL SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)104
9SLIDE STAINER MARKET, BY END USER105
9.1INTRODUCTION106
TABLE 53SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)106
9.2HOSPITALS AND DIAGNOSTIC LABORATORIES106
9.2.1NUMBER OF HOSPITALS AND DIAGNOSTIC LABORATORIES INCREASING IN SEVERAL COUNTRIES106
TABLE 54SLIDE STAINER MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)107
9.3ACADEMIC AND RESEARCH INSTITUTES108
9.3.1INCREASING INVESTMENTS FOR RESEARCH ON DISEASE DIAGNOSIS DRIVING SEGMENT GROWTH108
TABLE 55SLIDE STAINER MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)108
9.4PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES109
9.4.1INCREASING RESEARCH ON DRUG DISCOVERY TO DRIVE SEGMENT GROWTH109
TABLE 56SLIDE STAINER MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)109
9.5OTHER END USERS109
TABLE 57ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS110
TABLE 58SLIDE STAINER MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)110
10SLIDE STAINER MARKET, BY REGION111
10.1INTRODUCTION112
TABLE 59SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION)112
10.2NORTH AMERICA112
FIGURE 30NORTH AMERICA: CANCER INCIDENCE AND MORTALITY, 2012–2035113
FIGURE 31NORTH AMERICA: SLIDE STAINER MARKET SNAPSHOT113
TABLE 60NORTH AMERICA: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION)114
TABLE 61NORTH AMERICA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)114
TABLE 62NORTH AMERICA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)114
TABLE 63NORTH AMERICA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)115
TABLE 64NORTH AMERICA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)115
TABLE 65NORTH AMERICA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)115
TABLE 66NORTH AMERICA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)116
TABLE 67NORTH AMERICA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)116
10.2.1US116
10.2.1.1US to dominate global slide stainer market116
TABLE 68US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040117
TABLE 69US: KEY MACROINDICATORS117
TABLE 70US: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)118
TABLE 71US: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)118
TABLE 72US: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)118
TABLE 73US: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)119
10.2.2CANADA119
10.2.2.1Increasing prevalence of cancer to drive market growth119
TABLE 74CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025119
TABLE 75CANADA: KEY MACROINDICATORS120
TABLE 76CANADA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)120
TABLE 77CANADA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)121
TABLE 78CANADA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)121
TABLE 79CANADA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)121
10.3EUROPE122
FIGURE 32EUROPE: CANCER INCIDENCE AND MORTALITY, 2012–2035122
TABLE 80EUROPE: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION)123
TABLE 81EUROPE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)123
TABLE 82EUROPE: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)123
TABLE 83EUROPE: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)124
TABLE 84EUROPE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)124
TABLE 85EUROPE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)124
TABLE 86EUROPE: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)125
TABLE 87EUROPE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)125
10.3.1GERMANY125
10.3.1.1Increasing cancer screening initiatives to drive market growth125
TABLE 88GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025126
TABLE 89GERMANY: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)126
TABLE 90GERMANY: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)127
TABLE 91GERMANY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)127
TABLE 92GERMANY: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)127
 
10.3.2FRANCE128
10.3.2.1Government funding for cancer diagnosis and prevention to support market growth128
TABLE 93FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040128
TABLE 94FRANCE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)128
TABLE 95FRANCE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)129
TABLE 96FRANCE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)129
TABLE 97FRANCE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)129
10.3.3UK130
10.3.3.1Government initiatives to drive market growth130
TABLE 98UK: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)130
TABLE 99UK: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 100UK: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)131
TABLE 101UK: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)131
10.3.4ITALY131
10.3.4.1High incidence of cancer to support market growth131
TABLE 102ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025132
TABLE 103ITALY: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)132
TABLE 104ITALY: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)132
TABLE 105ITALY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)133
TABLE 106ITALY: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)133
10.3.5SPAIN133
10.3.5.1High incidence of chronic diseases to drive market growth133
TABLE 107SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025134
TABLE 108SPAIN: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)134
TABLE 109SPAIN: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)135
TABLE 110SPAIN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)135
TABLE 111SPAIN: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)135
10.3.6REST OF EUROPE136
TABLE 112LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040136
TABLE 113LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040137
TABLE 114ROE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)137
TABLE 115ROE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)137
TABLE 116ROE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)138
TABLE 117ROE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)138
 
10.4ASIA PACIFIC138
FIGURE 33ASIA PACIFIC: CANCER INCIDENCE AND MORTALITY, 2012–2035139
FIGURE 34ASIA PACIFIC: SLIDE STAINER MARKET SNAPSHOT140
TABLE 118APAC: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION)141
TABLE 119APAC: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)141
TABLE 120APAC: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)141
TABLE 121APAC: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 122APAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)142
TABLE 123APAC: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)142
TABLE 124APAC: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)143
TABLE 125APAC: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)143
10.4.1JAPAN143
10.4.1.1Advanced healthcare infrastructure to support market growth143
TABLE 126JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040144
TABLE 127JAPAN: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)144
TABLE 128JAPAN: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
TABLE 129JAPAN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)145
TABLE 130JAPAN: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)145
10.4.2CHINA145
10.4.2.1Increasing healthcare expenditure and funding to drive market growth145
TABLE 131CHINA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)146
TABLE 132CHINA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)146
TABLE 133CHINA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)146
TABLE 134CHINA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)147
10.4.3INDIA147
10.4.3.1Expanding healthcare sector to drive market growth147
TABLE 135INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025147
TABLE 136INDIA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)148
TABLE 137INDIA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)148
TABLE 138INDIA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)149
TABLE 139INDIA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)149
10.4.4REST OF ASIA PACIFIC149
TABLE 140INCIDENCE OF CANCER IN REST OF ASIA PACIFIC150
TABLE 141ROAPAC: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)150
TABLE 142ROAPAC: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)151
TABLE 143ROAPAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)151
TABLE 144ROAPAC: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)151
10.5LATIN AMERICA152
10.5.1INCREASING NUMBER OF CANCER SCREENING PROGRAMS TO SUPPORT MARKET GROWTH152
TABLE 145LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025152
TABLE 146LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025152
TABLE 147BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025153
TABLE 148LATAM: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)153
TABLE 149LATAM: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)154
TABLE 150LATAM: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)154
TABLE 151LATAM: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)154
TABLE 152LATAM: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)155
TABLE 153LATAM: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)155
TABLE 154LATAM: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)155
10.6MIDDLE EAST AND AFRICA156
10.6.1INCREASING INCIDENCE OF CANCER IN AFRICA TO SUPPORT MARKET GROWTH156
TABLE 155AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025156
TABLE 156MEA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION)156
TABLE 157MEA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)157
TABLE 158MEA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)157
TABLE 159MEA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)157
TABLE 160MEA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION)158
TABLE 161MEA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)158
TABLE 162MEA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION)158
 
11COMPETITIVE LANDSCAPE159
11.1OVERVIEW159
11.2KEY PLAYER STRATEGIES/RIGHT TO WIN159
TABLE 163OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SLIDE STAINER MARKET159
11.3REVENUE SHARE ANALYSIS160
FIGURE 35REVENUE ANALYSIS OF KEY PLAYERS IN SLIDE STAINER MARKET160
11.4MARKET SHARE ANALYSIS161
TABLE 164SLIDE STAINER MARKET: DEGREE OF COMPETITION161
11.5COMPANY EVALUATION MATRIX162
11.5.1STARS162
11.5.2PERVASIVE PLAYERS162
11.5.3EMERGING LEADERS162
11.5.4PARTICIPANTS162
FIGURE 36SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS163
11.6COMPANY EVALUATION MATRIX FOR SMES/START-UPS164
11.6.1PROGRESSIVE COMPANIES164
11.6.2RESPONSIVE COMPANIES164
11.6.3STARTING BLOCKS164
11.6.4DYNAMIC COMPANIES164
FIGURE 37SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR SMES/ START-UPS165
11.7COMPANY FOOTPRINT ANALYSIS166
11.7.1REGIONAL FOOTPRINT OF COMPANIES166
11.7.2PRODUCT FOOTPRINT OF COMPANIES167
11.7.3OVERALL FOOTPRINT OF COMPANIES168
11.8COMPETITIVE BENCHMARKING169
TABLE 165SLIDE STAINER MARKET: DETAILED LIST OF KEY START-UPS/SMES169
11.9COMPETITIVE SCENARIO170
11.9.1PRODUCT LAUNCHES/APPROVALS170
TABLE 166KEY PRODUCT LAUNCHES170
11.9.2DEALS171
TABLE 167KEY DEALS171
11.9.3OTHER DEVELOPMENTS172
TABLE 168OTHER KEY DEVELOPMENTS172
 
12COMPANY PROFILES173
12.1KEY PLAYERS173
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1F. HOFFMANN-LA ROCHE LTD.173
TABLE 169F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW173
FIGURE 38F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)174
12.1.2DANAHER177
TABLE 170DANAHER: BUSINESS OVERVIEW177
FIGURE 39DANAHER: COMPANY SNAPSHOT (2021)178
12.1.3PHC HOLDINGS CORPORATION181
TABLE 171PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW181
FIGURE 40PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)182
12.1.4MERCK KGAA184
TABLE 172MERCK KGAA: BUSINESS OVERVIEW184
FIGURE 41MERCK KGAA: COMPANY SNAPSHOT (2021)185
12.1.5AGILENT TECHNOLOGIES, INC.188
TABLE 173AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW188
FIGURE 42AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)189
12.1.6ABCAM PLC.191
TABLE 174ABCAM PLC.: BUSINESS OVERVIEW191
FIGURE 43ABCAM PLC.: COMPANY SNAPSHOT (2021)192
12.1.7BECTON, DICKINSON AND COMPANY194
TABLE 175BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW194
FIGURE 44BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)195
12.1.8SIEMENS HEALTHINEERS AG197
TABLE 176SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW197
FIGURE 45SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)198
12.1.9SAKURA FINETEK JAPAN CO., LTD.199
TABLE 177SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW199
12.1.10BIOCARE MEDICAL, LLC201
TABLE 178BIOCARE MEDICAL, LLC.: BUSINESS OVERVIEW201
12.1.11HARDY DIAGNOSTICS203
TABLE 179HARDY DIAGNOSTICS: BUSINESS OVERVIEW203
12.1.12GENERAL DATA COMPANY, INC.204
TABLE 180GENERAL DATA COMPANY, INC.: BUSINESS OVERVIEW204
12.1.13ELITECHGROUP205
TABLE 181ELITECHGROUP: BUSINESS OVERVIEW205
12.1.14BIOGENEX206
TABLE 182BIOGENEX.: BUSINESS OVERVIEW206
12.1.15HISTO-LINE LABORATORIES208
TABLE 183HISTO-LINE LABORATORIES: BUSINESS OVERVIEW208
12.1.16SLEE MEDICAL GMBH209
TABLE 184SLEE MEDICAL GMBH: BUSINESS OVERVIEW209
12.1.17AMOS SCIENTIFIC PTY LTD.210
TABLE 185AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW210
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2OTHER PLAYERS211
12.2.1MEDITE MEDICAL GMBH211
TABLE 186MEDITE MEDICAL GMBH: COMPANY OVERVIEW211
12.2.2CELLPATH LTD.212
TABLE 187CELLPATH LTD.: COMPANY OVERVIEW212
12.2.3DIAPATH S.P.A.213
TABLE 188DIAPATH S.P.A.: COMPANY OVERVIEW213
12.2.4BIO SB, INC.214
TABLE 189BIO SB, INC.: COMPANY OVERVIEW214
12.2.5ROCKLAND IMMUNOCHEMICALS, INC.214
TABLE 190ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW214
12.2.6CELL SIGNALING TECHNOLOGY, INC.215
TABLE 191CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW215
12.2.7DIAGNOSTIC BIOSYSTEMS, INC.216
TABLE 192DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW216
12.2.8DAKEWE BIOTECHNOLOGY CO., LTD.217
TABLE 193DAKEWE BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW217
12.2.9THERMO FISHER SCIENTIFIC, INC.218
TABLE 194THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW218
13APPENDIX219
13.1DISCUSSION GUIDE219
13.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL223
13.3AVAILABLE CUSTOMIZATIONS225
13.4RELATED REPORTS225
13.5AUTHOR DETAILS226